CD19 and acute lymphoblastic leukemia: Blinatumomab, a bi-specific T cell engager targeting concomitantly CD3 and CD19 molecules, proved its anti-leukemic effects in R/R Ph+ ALL as monotherapy [133] and in combination with second- and third-generation TKIs [167].